Core Insights - CytoDyn Inc. announced positive clinical findings for leronlimab in patients with advanced metastatic colorectal cancer (mCRC), with 3 out of 5 patients showing at least a partial response, including one complete response [1][3] - Dr. Benjamin Weinberg will present the final results at the ESMO Gastrointestinal Cancers Congress 2025 in Barcelona, Spain [2] - The results support the ongoing Phase II trial for relapsed/refractory microsatellite stable CRC, with the first patient recently dosed and additional patients being enrolled [3][5] Clinical Significance - The findings from the compassionate use protocol highlight a favorable safety profile for leronlimab and its potential clinical benefits in mCRC [3] - If confirmed, leronlimab could be effective for a variety of solid tumor types, and it has shown promise as a "priming" agent for patients with low PD-L1 levels who are unresponsive to checkpoint inhibitors [4] Company Overview - CytoDyn is a clinical-stage biotechnology company focused on developing leronlimab, a humanized IgG4 monoclonal antibody targeting CCR5, with applications in oncology, infectious diseases, and autoimmune conditions [6]

Core Insights - CytoDyn Inc. is set to present promising survival data for leronlimab at the ESMO Breast Cancer meeting, highlighting its potential in treating metastatic triple-negative breast cancer (mTNBC) [1][2] Company Overview - CytoDyn is a clinical-stage biotechnology company focused on developing leronlimab, a humanized IgG4 monoclonal antibody targeting the CCR5 receptor, which is implicated in various disease processes [4] Clinical Development - A review of previous clinical trials indicated favorable survival rates at 12, 24, and 36 months for patients treated with leronlimab compared to existing therapies [2] - The company confirmed that some patients with mTNBC, who had undergone four prior treatment lines, are alive over 48 months post-treatment, with some showing no evidence of disease [2] Upcoming Presentation - Dr. Jacob Lalezari and Dr. Richard Pestell will present at the ESMO conference on May 15, 2025, discussing the clinical development of leronlimab and its potential mechanism of action in long-term survivors [3]